MANNKIND CORP Acquisitions, Net of Cash Acquired
MANNKIND CORP (MNKD) reported Acquisitions, Net of Cash Acquired of $347.74 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-26.
Financial Statements › Cash Flow › Investing Activities
us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired · last filed 2026-02-26
- MANNKIND CORP payments to acquire businesses, net of cash acquired for the quarter ending 2022-12-31 was $242.00K.
- MANNKIND CORP payments to acquire businesses, net of cash acquired for the quarter ending 2022-09-30 was $0.00.
- MANNKIND CORP payments to acquire businesses, net of cash acquired for fiscal 2025 was $347.74M.
- MANNKIND CORP payments to acquire businesses, net of cash acquired for fiscal 2022 was $15.34M.
| Period end | Payments to Acquire Businesses, Net of Cash Acquired 3 month | Payments to Acquire Businesses, Net of Cash Acquired 6 month | Payments to Acquire Businesses, Net of Cash Acquired 9 month | Payments to Acquire Businesses, Net of Cash Acquired 12 month |
|---|---|---|---|---|
| 2025-12-31 | $347.74M 10-K · filed 2026-02-26 | |||
| 2022-12-31 | $242.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-26 | $242.00K derived: sum of 2 quarters · filed 2025-02-26 | $15.34M 10-K · filed 2025-02-26 | |
| 2022-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-07 | $15.10M 10-Q · filed 2023-11-07 | ||
| 2022-06-30 | $15.10M 10-Q · filed 2023-08-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Alto Neuroscience, Inc. (ANRO) | United States | $1.065B | -11.02 |
| Savara Inc (SVRA) | United States | $1.044B | -9.10 |
| MoonLake Immunotherapeutics (MLTX) | Switzerland | $1.031B | -5.43 |
| Pacira BioSciences, Inc. (PCRX) | United States | $1.020B | 69.03 |
| Janux Therapeutics, Inc. (JANX) | United States | $1.019B | -9.15 |
| Amphastar Pharmaceuticals, Inc. (AMPH) | United States | $1.116B | 10.93 |
| Corvus Pharmaceuticals, Inc. (CRVS) | United States | $0.994B | -23.25 |
| Seaport Therapeutics, Inc. (SPTX) | United States | $1.131B | |
| Kura Oncology, Inc. (KURA) | United States | $0.967B | -3.29 |
| Arbutus Biopharma Corp (ABUS) | $0.965B | 6.19 |